Cargando…

The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD–ACE2 Binding Interface

To date, some succeeding variants of SARS-CoV-2 have become more contagious. This virus is known to enter human cells by binding the receptor-binding domain (RBD) of spike protein with the angiotensin-converting enzyme 2 (ACE2), the latter being a membrane protein that regulates the renin–angiotensi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Semenov, Valentin A., Krivdin, Leonid B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788546/ https://www.ncbi.nlm.nih.gov/pubmed/36558067 http://dx.doi.org/10.3390/molecules27248938

Ejemplares similares

Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
por: Gurung, Arun Bahadur, et al.
Publicado: (2021)

Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding
por: Hoter, Abdullah, et al.
Publicado: (2022)

Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex
por: Ching, Wai-Yim, et al.
Publicado: (2022)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiangdong, et al.
Publicado: (2020)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiandong, et al.
Publicado: (2021)

Entropic contribution of ACE2 glycans to RBD binding
por: Mugnai, Mauro L., et al.
Publicado: (2023)

In silico investigations of heparin binding to SARS‐CoV‐2 variants with a focus at the RBD/ACE2 interface
por: Ali, Nemat, et al.
Publicado: (2022)

Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
por: Han, Pengcheng, et al.
Publicado: (2022)

Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction
por: Eka Saputri, Meliana, et al.
Publicado: (2022)

Investigation of potential inhibitor properties of violacein against HIV-1 RT and CoV-2 Spike RBD:ACE-2
por: Dogancı, Merve Ayse, et al.
Publicado: (2022)

Accommodating receptor flexibility and free energy calculation to reduce false positive binders in the discovery of natural products blockers of SARS-COV-2 spike RBD-ACE2 interface
por: Ogedjo, Marcelina, et al.
Publicado: (2021)

Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach
por: Muhseen, Ziyad Tariq, et al.
Publicado: (2020)

DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach
por: Silwal, Achut Prasad, et al.
Publicado: (2022)

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
por: Bertoglio, Federico, et al.
Publicado: (2021)

Stereochemical Study of the Super Large Tetrakis Alkaloid Alasmontamine A by Means of an Advanced Computational NMR
por: Semenov, Valentin A., et al.
Publicado: (2023)

Cross-species binding spectrum of ACE2 to SARS-CoV-2 RBD
por: Liao, Xihao, et al.
Publicado: (2022)

Exploring the disruption of SARS-CoV-2 RBD binding to hACE2
por: Carter, Camryn, et al.
Publicado: (2023)

Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2
por: Rathod, Shravan B., et al.
Publicado: (2020)

Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction
por: Cao, Wenpeng, et al.
Publicado: (2021)

A Collection of Designed Peptides to Target SARS-CoV-2 Spike RBD—ACE2 Interaction
por: Fernandez-Fuentes, Narcis, et al.
Publicado: (2021)

Differential Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern
por: Kim, Seonghan, et al.
Publicado: (2021)

Differential interactions between human ACE2 and spike RBD of SARS-CoV-2 variants of concern
por: Kim, Seonghan, et al.
Publicado: (2022)

Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics
por: Barton, Michael I, et al.
Publicado: (2021)

Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2
por: Chen, Chen, et al.
Publicado: (2021)

A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues
por: Chen, Chen, et al.
Publicado: (2022)

Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective
por: Borkotoky, Subhomoi, et al.
Publicado: (2022)

The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition
por: Hattori, Takamitsu, et al.
Publicado: (2020)

The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition
por: Hattori, Takamitsu, et al.
Publicado: (2021)

Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding
por: Yang, Li Jun, et al.
Publicado: (2021)

Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
por: Phelan, Thomas, et al.
Publicado: (2021)

Analyzing the interaction of human ACE2 and RBD of spike protein of SARS-CoV-2 in perspective of Omicron variant
por: Samanta, Arijit, et al.
Publicado: (2022)

Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions
por: Liu, Xiaofeng, et al.
Publicado: (2023)

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
por: Junker, Daniel, et al.
Publicado: (2022)

Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding
por: Lin, Sheng, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
por: Bertoglio, Federico, et al.
Publicado: (2021)

Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike
por: Mehdipour, Ahmad Reza, et al.
Publicado: (2021)

Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
por: Haycroft, Ebene R., et al.
Publicado: (2023)

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19
por: BR, Bharath, et al.
Publicado: (2020)

Electrostatic Interactions Are the Primary Determinant of the Binding Affinity of SARS-CoV-2 Spike RBD to ACE2: A Computational Case Study of Omicron Variants
por: Sang, Peng, et al.
Publicado: (2022)

Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics
por: Kelaidonis, Konstantinos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bn3gbe19co8e8rl0ff93kohg33